BioAtla, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BCAB Nasdaq 2830 www.bioatla.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioAtla, Inc.

BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... - Nov 13th, 2025 10:04 pm
BioAtla (BCAB) Q3 2025 Earnings Call Transcript - Nov 13th, 2025 3:07 pm
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Nov 13th, 2025 2:05 pm
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas - Nov 7th, 2025 7:00 am
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 - Nov 5th, 2025 6:00 am
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society - Oct 23rd, 2025 6:00 am
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - Oct 3rd, 2025 7:00 am
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA - Sep 8th, 2025 6:00 am
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress - Aug 7th, 2025 2:05 pm
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 - Aug 4th, 2025 6:00 am
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - Jul 17th, 2025 6:00 am
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress - Jul 3rd, 2025 6:00 am
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - Jun 2nd, 2025 6:00 am
BioAtla Inc (BCAB) Q1 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... - May 7th, 2025 1:21 am
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress - May 6th, 2025 2:05 pm
BioAtla to Participate in the Citizens Life Sciences Conference - Apr 30th, 2025 6:00 am
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025 - Apr 29th, 2025 6:00 am
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Apr 24th, 2025 6:00 am
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 23rd, 2025 8:05 am
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky - Mar 29th, 2025 7:24 am